Prognostic potential of serum CA 125 levels in danazol-treated patients with external endometriosis: a preliminary study.

International journal of fertility · 1990 · vol. 35(4) , pp. 226–9 · PMID:1977715 · W2433830014
article OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed
AI-generated summary by claude@2026-06, 2026-06-07

This study analyzed CA 125 level patterns in danazol-treated endometriosis patients, identifying four hormonal response types that differentiated good from poor prognoses and aided in treatment adjustment and relapse prediction.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Serum levels of CA 125 in 33 patients with progressive external endometriosis who were treated with 400 mg/day of Danazol for 16 weeks were assayed for an extended period (24-40 weeks), and changes in the CA 125 pattern were analyzed. Patterns of hormonal response were classified into four types. Prognosis for one type was good, whereas that for the other three types was poor. By making use of these patterns, we were able to determine more accurately the proper dose of Danazol, to alter the duration of treatment, and to predict relapse.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Antigens, Tumor-Associated, Carbohydrate Danazol Endometriosis Uterine Neoplasms Adult Antigens, Tumor-Associated, Carbohydrate Danazol Danazol Endometriosis Endometriosis Endometriosis Female Humans Japan Japan Middle Aged Neoplasm Recurrence, Local Predictive Value of Tests Prognosis Uterine Neoplasms

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:10.587122+00:00
License: CC0 · commercial use OK